<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00084279</url>
  </required_header>
  <id_info>
    <org_study_id>AGHC-002</org_study_id>
    <nct_id>NCT00084279</nct_id>
  </id_info>
  <brief_title>CIFN and IFN γ-1b With or Without Ribavirin for Treatment of Chronic Hepatitis C (Nonresponders)</brief_title>
  <official_title>Safety and Tolerability of Consensus Interferon-Alpha (CIFN) Plus Interferon Gamma-1b (IFN-γ 1b) With or Without Ribavirin (RBV) in the Treatment of Patients With Chronic Hepatitis C Who Are Non-Responders to PEG-IFN-a (2a or 2b) Plus RBV</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>InterMune</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>InterMune</source>
  <brief_summary>
    <textblock>
      To evaluate the safety and tolerability of two different doses of Consensus Interferon-Alpha&#xD;
      and Interferon Gamma-1b with or without ribavirin in patients with chronic hepatitis C who&#xD;
      are non-responders to PEG-IFN-a 2a or PEG-IFN-a 2b plus ribavirin.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2004</start_date>
  <completion_date type="Actual">April 2006</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Virologic response defined as &gt;2 log (base 10) reduction in HCV RNA</measure>
    <time_frame>72 weeks</time_frame>
  </primary_outcome>
  <enrollment type="Actual">81</enrollment>
  <condition>Chronic Hepatitis C</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Consensus Interferon-Alpha, Interferon Gamma-1b, Ribavirin</intervention_name>
    <description>interferon gamma-1b: 0.25 and 0.5 mL, SQ, 3x per week interferon alfacon: 0.3 mL and 0.5 mL, SQ, once a day Ribavirin: 2 capsules in a.m., 3 capsules in p.m.; daily</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed, written, informed consent from the patient or legal representative before any&#xD;
             study-specific procedures are performed&#xD;
&#xD;
          2. Male or female 18 years of age or older&#xD;
&#xD;
          3. Chronic hepatitis C infection based on history of positive serum anti-HCV antibody&#xD;
             and/or HCV RNA&#xD;
&#xD;
          4. Patients must have documented failure to respond to past treatment with PEG-Intron or&#xD;
             Pegasys plus RBV.&#xD;
&#xD;
          5. Liver biopsy within 3 years of screening documenting chronic liver disease consistent&#xD;
             with chronic hepatitis C&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with any history of decompensated liver disease including but not restricted&#xD;
             to portal hypertension as manifested by gastroesophageal varices, variceal bleeding,&#xD;
             ascites, or encephalopathy&#xD;
&#xD;
          2. Specific laboratory abnormalities at Screening&#xD;
&#xD;
          3. Patients who were HCV RNA negative during prior pegylated interferon plus ribavirin&#xD;
             treatment, but who relapsed during follow-up&#xD;
&#xD;
          4. Recent depression or psychiatric disorders&#xD;
&#xD;
          5. Known HIV infection or positive HIV antibody test at Screening&#xD;
&#xD;
          6. Chronic hepatitis B infection or positive hepatitis B surface antigen (HBsAg) at&#xD;
             Screening&#xD;
&#xD;
          7. Unstable or uncontrolled thyroid disease&#xD;
&#xD;
          8. Presence or history of non-HCV chronic liver disease&#xD;
&#xD;
          9. History of unstable or deteriorating cardiovascular or cerebrovascular disease within&#xD;
             6 months prior to Screening&#xD;
&#xD;
         10. Current or history of neurologic disorder within a specified time frame&#xD;
&#xD;
         11. A disease known to cause significant alteration in immunologic function including&#xD;
             hematological malignancy, sarcoidosis or autoimmune disorder (e.g. rheumatoid&#xD;
             arthritis, systemic lupus erythematosis, leukemia, lymphoma, autoimmune thyroid&#xD;
             disease, scleroderma, psoriasis, inflammatory bowel disease, multiple sclerosis etc.)&#xD;
&#xD;
         12. History of major organ transplantation (i.e., liver, kidney, lung, or heart) with an&#xD;
             existing functional graft, including bone marrow transplant or stem cell transplant&#xD;
&#xD;
         13. Concurrent therapy with immunosuppressive drugs or cytotoxic agents such as&#xD;
             cyclosporine, azathioprine, chronic systemic corticosteroids, or chemotherapeutic&#xD;
             agent(s) (e.g., cyclophosphamide, methotrexate, or cancer chemotherapy) or radiation&#xD;
             therapy&#xD;
&#xD;
         14. Pregnant or lactating women&#xD;
&#xD;
         15. Liver biopsy within the past three years documenting cirrhosis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthew McClure, MD</last_name>
    <role>Study Director</role>
    <affiliation>InterMune</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>InterMune, Inc.</name>
      <address>
        <city>Brisbane</city>
        <state>California</state>
        <zip>94005</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2009</verification_date>
  <study_first_submitted>June 9, 2004</study_first_submitted>
  <study_first_submitted_qc>June 10, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 11, 2004</study_first_posted>
  <last_update_submitted>July 1, 2009</last_update_submitted>
  <last_update_submitted_qc>July 1, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 3, 2009</last_update_posted>
  <keyword>Chronic Hepatitis C</keyword>
  <keyword>Liver</keyword>
  <keyword>Pegylated</keyword>
  <keyword>Interferon</keyword>
  <keyword>Alpha</keyword>
  <keyword>Gamma</keyword>
  <keyword>Ribavirin</keyword>
  <keyword>Combination</keyword>
  <keyword>Nonresponder</keyword>
  <keyword>Pegasys</keyword>
  <keyword>PegIntron</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Interferon-gamma</mesh_term>
    <mesh_term>Interferon alfacon-1</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

